Literature DB >> 7709418

Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs.

P D Hurn1, R C Koehler, K K Blizzard, R J Traystman.   

Abstract

BACKGROUND AND
PURPOSE: Postischemic metabolic injury may be mediated by acidosis and tissue bicarbonate depletion, with consequent-iron mobilization and oxygen radical formation during reperfusion. We have previously shown that reducing intracellular pH to below 5.7 and bicarbonate ion to below 1 to 2 mmol/L during hyperglycemic ischemia produces a profound secondary deterioration of brain ATP and cerebral blood flow during reperfusion. This study tested the hypothesis that pretreatment with free deferoxamine ameliorates metabolic decay and delayed hypoperfusion after global hyperglycemic ischemia. In addition, deferoxamine conjugated to a high-molecular-weight starch was administered to determine the importance of an intravascular site of action. Iron-loaded deferoxamine was used to determine whether the iron chelation properties of deferoxamine are important to postischemic viability as distinguished from the agent's significant radical scavenging potential.
METHODS: Cerebral ATP, phosphocreatine, and pH were measured by 31P magnetic resonance spectroscopy in anesthetized dogs. Tissue bicarbonate concentration was calculated from the Henderson-Hasselbalch equation. Incomplete cerebral ischemia was produced by intracranial pressure elevation for 30 minutes with plasma glucose at 540 +/- 15 mg/dL. Free deferoxamine, saline vehicle, hydroxyethyl starch-conjugated deferoxamine, hydroxyethyl starch vehicle, and deferoxamine loaded with equimolar ferric chloride were administered intravenously in five groups of dogs. The dose of deferoxamine was 50 mg/kg before ischemia, 50 mg/kg at the onset of reperfusion, and 50 mg/kg over the 180-minute reperfusion period.
RESULTS: Ischemic hemispheric blood flow (mean, 6 to 8 mL/min per 100 g), intracellular pH (5.7 to 6.0), and bicarbonate levels (1 to 2 mmol/L) were similar in all groups. During reperfusion, cerebral pH and bicarbonate recovered only in the free-deferoxamine group. Both ATP and phosphocreatine initially increased in all groups, but recovery was sustained only in the free-deferoxamine group. Secondary losses of energy phosphates and cerebral oxygen consumption were observed in all other groups, accompanied by progressive reduction of perfusion.
CONCLUSIONS: These data support the hypothesis that iron catalyzed oxygen radical production plays an important role in acidosis-mediated mechanisms of ischemic brain injury. The results with free and iron-loaded deferoxamine suggest that iron scavenging is an important, but not necessarily the principal, component of this mechanism. The poor recovery seen with conjugated deferoxamine indicates that the beneficial action of deferoxamine is not localized within the intravascular compartment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7709418     DOI: 10.1161/01.str.26.4.688

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  15 in total

1.  Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin.

Authors:  K Zaman; H Ryu; D Hall; K O'Donovan; K I Lin; M P Miller; J C Marquis; J M Baraban; G L Semenza; R R Ratan
Journal:  J Neurosci       Date:  1999-11-15       Impact factor: 6.167

Review 2.  Hypoxia-inducible factor prolyl hydroxylase inhibition: robust new target or another big bust for stroke therapeutics?

Authors:  Saravanan S Karuppagounder; Rajiv R Ratan
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-14       Impact factor: 6.200

3.  Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system.

Authors:  Ambreena Siddiq; Issam A Ayoub; Juan C Chavez; Leila Aminova; Sapan Shah; Joseph C LaManna; Stephanie M Patton; James R Connor; Robert A Cherny; Irene Volitakis; Ashley I Bush; Ingrid Langsetmo; Todd Seeley; Volkmar Gunzler; Rajiv R Ratan
Journal:  J Biol Chem       Date:  2005-10-13       Impact factor: 5.157

4.  Effects of deferoxamine on brain injury after transient focal cerebral ischemia in rats with hyperglycemia.

Authors:  Yingqi Xing; Ya Hua; Richard F Keep; Guohua Xi
Journal:  Brain Res       Date:  2009-07-23       Impact factor: 3.252

5.  Activation of c-Jun-N-terminal kinase in a rat model of intracerebral hemorrhage: the role of iron.

Authors:  Shu Wan; Renya Zhan; Shusen Zheng; Ya Hua; Guohua Xi
Journal:  Neurosci Res       Date:  2008-11-30       Impact factor: 3.304

6.  Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease.

Authors:  Donna W Lee; Subramanian Rajagopalan; Ambreena Siddiq; Roberto Gwiazda; Lichuan Yang; M Flint Beal; Rajiv R Ratan; Julie K Andersen
Journal:  J Biol Chem       Date:  2009-08-13       Impact factor: 5.157

7.  Augmentation of poly(ADP-ribose) polymerase-dependent neuronal cell death by acidosis.

Authors:  Jian Zhang; Xiaoling Li; Herman Kwansa; Yun Tai Kim; Liye Yi; Gina Hong; Shaida A Andrabi; Valina L Dawson; Ted M Dawson; Raymond C Koehler; Zeng-Jin Yang
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

Review 8.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

9.  A possible novel anti-inflammatory mechanism for the pharmacological prolyl hydroxylase inhibitor 3,4-dihydroxybenzoate: implications for use as a therapeutic for Parkinson's disease.

Authors:  Shankar J Chinta; Subramanian Rajagopalan; Abirami Ganesan; Julie K Andersen
Journal:  Parkinsons Dis       Date:  2012-05-14

Review 10.  Promise of neurorestoration and mitochondrial biogenesis in Parkinson's disease with multi target drugs: an alternative to stem cell therapy.

Authors:  Moussa Bh Youdim; Young J Oh
Journal:  Exp Neurobiol       Date:  2013-09-30       Impact factor: 3.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.